Dr. Pol Boudes to leave CymaBay Therapeutics — 4 insights

Clinical-stage biopharmaceutical company CymaBay Therapeutics will lose its CMO Pol Boudes, MD, who is leaving the company on his own accord.

Advertisement

What you should know:

1. Dr. Boudes will resign Sept. 30.

2. CymaBay began searching for his replacement.

3. Gideon Hirschfield, MD, will provide medical and clinical support while the company searches for a fulltime replacement.

4. CymaBay is developing treatments for liver and other chronic diseases.

More articles on surgery center:
ASC supply chain tip of the day: Rely on data
Prevent cross contamination with single sterile IV start kits
Medline to Expand Southeast Distribution with New North Carolina Center

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.